Somatic mutation profiling of hobnail variant of papillary thyroid carcinoma
- Luca Morandi1,
- Alberto Righi2,
- Francesca Maletta3,
- Paola Rucci4,
- Fabio Pagni5,
- Marco Gallo6,
- Sabrina Rossi7,
- Leonardo Caporali8,
- Anna Sapino9,
- Ricardo V Lloyd10 and
- Sofia Asioli1⇑
- 1Department of Biomedical and Neuromotor Sciences, Section of Anatomic Pathology ‘M. Malpighi’ at Bellaria Hospital, University of Bologna, Bologna, Italy
- 2Department of Pathology, Rizzoli Institute, (IRCCS), Bologna, Italy
- 3Department of Medical Sciences, University of Turin, Turin, Italy
- 4Section of Hygiene and Biostatistics, University of Bologna, Bologna, Italy
- 5Department of Pathology, University of Milano Bicocca, Monza, Italy
- 6Oncological Endocrinology Unit, Department of Medical Sciences, AOU Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy
- 7Department of Pathology, Regional Hospital, Treviso, Italy
- 8Istituto delle Scienze Neurologiche di Bologna (IRCCS), Bellaria Hospital, Bologna, Italy
- 9Institute for Cancer Research and Treatment (IRCCS), Candiolo, Italy
- 10University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA
- Correspondence should be addressed to S Asioli; Email: sofia.asioli3{at}unibo.it
Abstract
Hobnail variant of papillary thyroid carcinoma (HPTC) represents a recently described, aggressive and rare group of thyroid tumors with poorly understood pathogenesis. Molecular data about this group of cancers are few, and a more detailed molecular characterization of these tumors is needed. The main objective of the study is to define a comprehensive molecular typing of HPTC. Eighteen patients affected by HPTC, including eighteen primary tumors and four lymph node metastases, were screened for NRAS, KRAS, HRAS, BRAF, TP53, PIK3CA, hTERT, PTEN, CDKN2A, EGFR, AKT1, CTNNB1 and NOTCH1 gene mutations. Sequencing is conducted on the MiSEQ system, and molecular data are compared with clinical-pathologic data and follow-up. The patients include 14 women and 4 men. Ages range from 23 to 87 years. All 18 primary tumors of HPTC showed ≥30% hobnail features. BRAF and TP53 mutations are by far the most common genetic alterations in primary HPTC (72.2% and 55.6%, respectively), followed by hTERT (44.4%), PIK3CA (27.8%), CTNNB1 (16.7%), EGFR (11.1%), AKT1 (5.5%) and NOTCH1 (5.5%). The mutational pattern in primary tumors and metastasis was usually maintained. Univariate Cox regression analyses with bootstrap procedure indicated a significantly increased mortality risk in patients harboring BRAF mutation and BRAF mutation associated with TP53 and/or PIK3CA mutations. The detection of these multiple mutations appears to allow the identification of a subset of more aggressive tumors within the group and to bear information that should be useful for prognostic stratification of these patients including the planning of adjuvant therapy.
- Received 18 December 2016
- Accepted 6 January 2017
- Made available online as an Accepted Preprint 6 January 2017
- © 2017 Society for Endocrinology